C4X Discovery Holdings PLC Result of AGM (0123C)
January 16 2018 - 5:46AM
UK Regulatory
TIDMC4XD
RNS Number : 0123C
C4X Discovery Holdings PLC
16 January 2018
C4X Discovery Holdings plc
("C4XD" or the "Company")
Result of AGM
16 January 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces that at its Annual
General Meeting, held today at 10:00 am at Panmure Gordon &
Co., One New Change, London EC4M 9AF, all resolutions were duly
passed.
--ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer
07801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley (Corporate Finance)
020 7886 2500
Tom Salvesen (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal 0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R) )
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction,
diabetes and inflammation with a number of new drug candidates
identified and further progress made towards the clinic. In
selecting new targets C4X Discovery will focus on the high-value
disease areas of inflammation and neurodegeneration, and will
continue to maximise value from opportunistic areas, for example,
immuno-oncology, addiction, and diabetes.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGBGGDBUSBBGIL
(END) Dow Jones Newswires
January 16, 2018 05:46 ET (10:46 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024